Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

被引：0
|
作者：
Corassa, Marcelo [1 ]
Abreu, Rodrigo Fonseca [2 ]
Cordeiro de Lima, Vladmir Claudio [1 ]
Torrezan, Giovana Tardim [3 ,4 ]
Cavalher, Felicia Peterson [1 ]
Silva, Tullio Novaes [2 ]
de Oliveira, Thiago Bueno [1 ]
Freitas, Helano Carioca [1 ]
Carraro, Dirce Maria [3 ,4 ]
Costa, Felipe D'Almeida [2 ]
机构：
[1] AC Camargo Canc Ctr, Dept Med Oncol, R Prof Antonio Prudente, Sao Paulo, Brazil
[2] Dept Pathol, R Prof Antonio Prudente, Sao Paulo, Brazil
[3] AC Camargo Canc Ctr, Genom & Mol Biol Grp, Int Res Center CIPE, Sao Paulo, Brazil
[4] Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, Brazil
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
SQUAMOUS-CELL CARCINOMA; HISTOLOGIC TRANSFORMATION; KINASE INHIBITORS; FREQUENCY; CANCER;
D O I：
10.1200/PO.22.00367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
    de Garibay, G. Ruiz
    Roch, B.
    Garrido Lopez, P.
    Isla, D.
    Aguado, C.
    Callejo Perez, A.
    Marse Fabregat, R.
    Garcia Campelo, M. R.
    Blasco Cordellat, A.
    Sanchez Torres, J. M.
    Bernabe Caro, R.
    Juan Vidal, O. J.
    Carpeno, J. De Castro
    Franco, F. F.
    Ramos Garcia, I.
    Gomez Rueda, A.
    Conde Gallego, E.
    Ponce Aix, S.
    Paz-Ares, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
  • [22] Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
    Choudhury, Noura J.
    Marra, Antonio
    Yang, Soo-Ryum
    Falcon, Christina J.
    Heller, Glenn
    Kris, Mark G.
    Reis-Filho, Jorge S.
    Riely, Gregory J.
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
    Schoenfeld, Adam J.
    Chan, Joseph M.
    Kubota, Daisuke
    Sato, Hiroki
    Rizvi, Hira
    Daneshbod, Yahya
    Chang, Jason C.
    Paik, Paul K.
    Offin, Michael
    Arcila, Maria E.
    Davare, Monika A.
    Shinde, Ujwal
    Pe'er, Dana
    Rekhtman, Natasha
    Kris, Mark G.
    Somwar, Romel
    Riely, Gregory J.
    Ladanyi, Marc
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2654 - 2663
  • [24] Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib
    Yu, Helena Alexandra
    Kerr, Keith
    Rolfo, Christian Diego
    Fang, Jian
    Finocchiaro, Giovanna
    Wong, Kam-Hung
    Veillon, Remi
    Kato, Terufumi
    Yang, James Chih-Hsin
    Nadal, Ernest
    Raskin, Jo
    Le, Xiuning
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    OBrate, Aurora
    Stroh, Christopher
    Piske, Nadine
    Boesler, Carsten
    Yang, Jinji
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [26] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Tokito, Takaaki
    Takeda, Masayuki
    Tanaka, Hiroshi
    Chikamori, Kenichi
    Daga, Haruko
    Kijima, Takashi
    Ohashi, Kadoaki
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
  • [27] EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
    Hara, Reina
    Kanazu, Masaki
    Iwai, Ami
    Kuge, Tomoki
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    THORACIC CANCER, 2021, 12 (09) : 1441 - 1444
  • [28] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [29] SMARCA4-mediated chromatin remodeling regulates osimertinib resistance in EGFR-mutant lung adenocarcinoma
    De Miguel, Fernando J.
    Cai, Wesley L.
    Melnick, Mary Ann
    Robles-Oteiza, Camila
    Wurtz, Anna
    Toki, Maria I.
    Rimm, David L.
    Homer, Robert
    Nguyen, Don X.
    Politi, Katerina A.
    CANCER RESEARCH, 2022, 82 (12)
  • [30] The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
    Kibirova, Albina
    Mattes, Malcolm D.
    Smolkin, Matthew
    Ma, Patrick C.
    CASE REPORTS IN ONCOLOGY, 2019, 12 (03): : 765 - 776
12345